Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Patent litigation for provider of automatic order fulfillment systems
The firm served as lead counsel on behalf of a provider of automatic order fulfillment systems in a patent infringement suit brought by a pharmacy more
$30 million senior-secured revolving credit facility to a domestic and international manufacturer and distributor of cellular telephones
Represented a commercial finance company, as agent and lender, in connection with $30 million senior-secured revolving credit facility provided to a more
Acquisition for U.S. and Canadian architectural and construction products company
Represented a U.S. and Canadian architectural and construction products company in an acquisition. more
ERP licensing & systems integration transactions for private retail company

Represented private retail company in negotiation of agreement with Logic Information Systems to more